布地奈德/福莫特罗吸入治疗难治性哮喘疗效观察

目的研究布地奈德/福莫特罗吸入治疗难治性哮喘的疗效。方法将2011年1月-2012年12月广东省梅州市人民医院收治的90例难治性喘患者纳入研究对象,随机分为给予布地奈德/福莫特罗粉(160μg/4.5μg)吸入治疗的观察组和给予布地奈德(100μg)、沙丁胺醇(100μg)吸入治疗的对照组,检测气道功能及炎症水平。检测最大呼气流速(PEF)、第1秒用力呼气容积(FEV1)、用力肺活量(FVC),并计算一秒率(FEV1/FVC%)。结果观察组患者IL-5、IL-17、IL-33水平[(61.4±13.4)、(5.1±1.1)、(10.8±2.0)]μg/L均低于对照组,PEF(74.8±10.4)ml/s、FEV1/FVC%(8.3±9.8)均高于对照组。结论布地奈德/福莫特罗吸入治疗有助于控制炎症反应、改善气道功能。

Objective To study the effect of budesonide/formoterol in treating refractory asthma. Methods Patients with refractory asthma enrolled and were randomly divided into observation group given budesonide/formoterol（160μg/4.5μg）and control group given budesonide（100μg） and albuterol（100μg）. Then inflammatory factor level, respiratory function index were detected. Results IL-5, IL-17, IL-33 levels[（61.4±13.4）、（5.1±1.1）、（10.8±2.0）]μg/L of observation group were lower than those of control group;PEF（74.8±10.4）ml/s, FEV 1/FVC%（8.3±9.8） of observation group were higher than those of control group. Conclusion Budesonide/formoterol can more effectively control airway inflammation and improve respiratory function.